Skadden represented Valeant Pharmaceuticals International Inc. in resolving an investigation by the Federal Trade Commission into Valeant's May 2015 acquisition of Paragon Holdings I, Inc. and its subsidiary Paragon Vision Sciences.

BACK TO TOP